This randomized phase II/III trial studies the side effects and best dose of nivolumab and ipilimumab when given together with or without sargramostim and to see how well they work in treating patients with stage III-IV melanoma that cannot be removed by surgery.
Contact site for start date.
Please contact ClinicalResearch@sutterhealth.org about Study EA6141.
View study details on ClinicalTrials.gov
Subjects, 18 y/o and older, with unresectable stage III or stage IV melanoma; and must have histological or cytological confirmation of melanoma that is metastatic or unresectable and clearly progressive
June 01, 2018